FXS6837 for the Treatment of IgAN Patients

Summary

This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients. About 60 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of FXS6837 or placebo capsules orally according to protocol.

Timeline

Start

2026-03-31

Primary completion

2027-09-12

Completion

2027-11-14

Drugs

Indications